Trial Information

Summary: Phase II trial of perioperative gemcitabine and cisplatin chemotherapy in resected pleural mesothelioma

The primary objective of the study is to determine the progression-free survival and overall survival of patients receiving perioperative (before surgery and/or after surgery) chemotherapy followed by adjuvant (after surgery) radiation therapy for resected pleural mesothelioma. The secondary objectives are to assess the toxicity of perioperative cisplatin and gemcitabine chemotherapy in this patient population.

For patients referred prior to surgery: Chemotherapy will be given for 6 weeks followed by surgical removal of disease-affected lung tissue. This will be followed by another 6 weeks of chemotherapy, radiation therapy and another 6 weeks of chemotherapy.

For patients referred after surgery: Surgical removal of disease-affected lung tissue will be followed by 9 weeks of chemotherapy. This will be followed by radiation therapy and another 9 weeks of chemotherapy.

Patient Inclusion/Exclusion Criteria:

Patients will be adults who have histologically confirmed malignant pleural mesothelioma and will have received no prior chemotherapeutic regimens.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.